<?xml version="1.0" encoding="UTF-8"?>
<p>Seroprevalence data are presented in 
 <xref ref-type="fig" rid="pntd.0006533.g005">Fig 5</xref>. The seroprevalence of DENV ranged from less than 1% [
 <xref rid="pntd.0006533.ref062" ref-type="bibr">62</xref>,
 <xref rid="pntd.0006533.ref065" ref-type="bibr">65</xref>,
 <xref rid="pntd.0006533.ref068" ref-type="bibr">68</xref>,
 <xref rid="pntd.0006533.ref140" ref-type="bibr">140</xref>,
 <xref rid="pntd.0006533.ref143" ref-type="bibr">143</xref>,
 <xref rid="pntd.0006533.ref168" ref-type="bibr">168</xref>] to 100% in a study conducted among 442 pregnant women in the Caribbean Islands (St Kitts Nevis and Jamaica) [
 <xref rid="pntd.0006533.ref094" ref-type="bibr">94</xref>]. Among studies that performed IgG ELISA, the highest seroprevalence rates were observed in the Caribbean region and in the Americas. Studies conducted in Asia highlighted lower seroprevalence rates, ranging from 50 to 75%. Seroprevalence rates appeared to be the lowest in Africa, ranging from 0 to 35%.
</p>
